Neurology News Network for the week ending June 6th, 2026. [WATCH TIME: 5 minutes]
Weekly Recap
Advertisement
GLP-1s Improve MS Physical Activity, BLA Submitted for Z-Rostudirsen, Ofatumumab Outperforms Rituximab in NMOSD Study
Published: | Updated:
Neurology News Network for the week ending May 30, 2026. [WATCH TIME: 4 minutes]
Advertisement
Neurology News Network for the week ending May 16th, 2026. [WATCH TIME: 4 minutes]
Neurology News Network for the week ending May 16th, 2026. [WATCH TIME: 5 minutes]
Neurology News Network for the week ending May 9th, 2026. [WATCH TIME: 5 minutes]
Neurology News Network for the week ending May 2nd, 2026. [WATCH TIME: 5 minutes]
Advertisement
Neurology News Network for the week ending April 25th, 2026. [WATCH TIME: 5 minutes]
Neurology News Network for the week ending April 18, 2026. [WATCH TIME: 5 minutes]
Modafinil Effective for Treating EDS, Ravulizumab Controls NMOSD, Regardless of Rituximab Use, Reviewing 2026 Q1 FDA Approvals
Published: | Updated:
Neurology News Network for the week ending April 11, 2026. [WATCH TIME: 4 minutes]
FDA Approves Higher Dose Nusinersen, Fatigue, EDS Uncorrelated with OSA, Shifting Neurologic Research in Down Syndrome
Published: | Updated:
Neurology News Network for the week ending April 4, 2026. [WATCH TIME: 5 minutes]
Advertisement
FDA Approvals Highlight Rare Neurologic Therapies as Purple Day Raises Awareness for Epilepsy
Published: | Updated:
Neurology News Network for the week ending March 28, 2026. [WATCH TIME: 4 minutes]
Solriamfetol Reduces EDS, Xanomeline Trospium evaluated for Agitation in AD, Otaneda Explains radiologic markers in MS trials
Published: | Updated:
Neurology News Network for the week ending March 21, 2026. [WATCH TIME: 4 minutes]
FDA Expands Leucovorin Indication, Key Phase 3 Studies Revealed at MDA 2026, Crowley on the Future of Neuromuscular Medicine
Published: | Updated:
Neurology News Network for the week ending March 14, 2026. [WATCH TIME: 4 minutes]
Fenebrutinib Achieves Primary End Point in Head-to-Head Trial, GB221 Begins First-in-Person Trial for SMA1, Air Pollution Linked to Increased AD Risk
Published: | Updated:
Neurology News Network for the week ending March 7, 2026. [WATCH TIME: 5 minutes]
Efgartigimod Meets Primary Endpoint, Neurologic Outcomes not Improved with EryDex, Elevidys Associated with Stabilization in DMD
Published: | Updated:
Neurology News Network for the week ending February 28, 2026. [WATCH TIME: 5 minutes]
Balt's Squid Receives Premarket Approval, Pitolisant Tablets Granted Extended Approval Indication, I-ACQUIRE Displays Promising Short-Term Outcomes
Published: | Updated:
Neurology News Network for the week ending February 21, 2026. [WATCH TIME: 5 minutes]
Regenxbio Receives CRL from FDA, NDA for Takeda’s Oveporextin Accepted, ACP Abandons use of “Provider”
Published: | Updated:
Neurology News Network for the week ending February 14, 2026. [WATCH TIME: 4 minutes]
Phase 3 EMBARK Data Released, CTE Associated with Dementia Risk, Pilavapadin Heads to Phase 3 Pain Studies
Published: | Updated:
Neurology News Network for the week ending January 31, 2025. [WATCH TIME: 4 minutes]
Phase 3 Data Levacetylleucine Data in Niemann-Pick, FDA Requests Data for Deramiocel to Fulfill Submission, COYA 302 and Frontotemporal Dementia
Published: | Updated:
Neurology News Network for the week ending January 24, 2025. [WATCH TIME: 4 minutes]
Efgartigimod Application Submitted for Seronegative gMG, EC Approves High-Dose Nusinersen, Copper Histidinate Gains First Approval for Menkes Disease
Published: | Updated:
Neurology News Network for the week ending January 17, 2025. [WATCH TIME: 4 minutes]
Phase 2 BREAKTHROUGH Data Released, Liriglutide Effective in Obesity-Related Migraine, FDA Approves Generic Glatiramer Acetate Injection
Published: | Updated:
Neurology News Network for the week ending January 10, 2025. [WATCH TIME: 4 minutes]
REVITALYZ Trial Enrollment Complete, PIPE-307 Fails Phase 2 Trial, AMX0114 Safe in Phase 1 LUMINA Study
Published: | Updated:
Neurology News Network for the week ending January 3, 2025. [WATCH TIME: 4 minutes]
Neurology News Network for the week ending December 27, 2025. [WATCH TIME: 4 minutes]
FDA Approves Inebilizumab for Myasthenia Gravis, Phase 3 PREVAiLS Study Launched, Tolebrutinib Fails Phase 3 PERSEUS Study
Published: | Updated:
Neurology News Network for the week ending December 20, 2025. [WATCH TIME: 4 minutes]
NDA Accepted for Narcolepsy Oxybate TRN-257, Gene Therapy ETX101 Early Promise in Dravet, Bexicaserin's Impact on Developmental Encephalopathies
Published: | Updated:
Neurology News Network for the week ending December 13, 2025. [WATCH TIME: 4 minutes]
FDA Approves Intrathecal Version of Zolgensma, Ozempic Falls Short in EVOKE Trials, Asundexian Meets End Point in Stroke Prevention Trial
Published: | Updated:
Neurology News Network for the week ending November 29, 2025. [WATCH TIME: 4 minutes]
FDA Makes Label Change to Elevidys, ALS Prevalence to Increase by 2040, CNM-Au8 NDA Submitted
Published: | Updated:
Neurology News Network for the week ending November 22, 2025. [WATCH TIME: 4 minutes]
BBP-418 Success in LGMD, Alixorexton Improves Narcolepsy Symptoms, Fenebrutinib Meets Phase 3 End Points
Published: | Updated:
Neurology News Network for the week ending November 15, 2025. [WATCH TIME: 4 minutes]
Neflamapimod Phase 3 Trial in DLB, Troriluzole Gets CRL for SCA, Periodontal Disease and Stroke Risk
Published: | Updated:
Neurology News Network for the week ending November 8, 2025. [WATCH TIME: 4 minutes]
Neurology News Network for the week ending November 1, 2025. [WATCH TIME: 3 minutes]
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Advancing the Field: Stem Cell Therapies and the Future of Parkinson Disease Treatment
2
Current and Emerging Strategies for Managing Huntington Disease Symptoms: Karen Anderson, MD
3
Improving Recognition and Treatment of Hyperkinetic Movement Disorders: Zoltan Mari, MD
4
Differentiating Pathologic Features of Alzheimer Disease and Lewy Body Dementia: Charbel Moussa, MBBS, PhD
5